Marinus Pharmaceuticals

OverviewSuggest Edit

Marinus Pharmaceuticals is a clinical stage biopharmaceutical company. It is engaged in the development and commercialization of ganaxolone. The Company develops treatments for patients suffering from drug-resistant seizures and neuropsychiatric disorders. 

TypePublic
Founded2003
HQWayne, PA, US
Websitemarinuspharma.com

Latest Updates

Employees (est.) (Dec 2019)40(-2%)
Revenue (FY, 2016)$0
Share Price (Jan 2021)$12.6 (-1%)
Cybersecurity ratingAMore

Key People/Management at Marinus Pharmaceuticals

Scott Braunstein

Scott Braunstein

Chief Executive Officer & Director
Lisa M. Caperelli

Lisa M. Caperelli

Executive Director, Investor & Strategic Relations
Edward F. Smith

Edward F. Smith

Vice President, Chief Financial Officer, Secretary and Treasurer
Enrique J. Carrazana

Enrique J. Carrazana

Director
Joe Hulihan

Joe Hulihan

Chief Medical Officer
Michael R. Dougherty

Michael R. Dougherty

Director
Show more

Marinus Pharmaceuticals Office Locations

Marinus Pharmaceuticals has an office in Wayne
Wayne, PA, US (HQ)
170 N Radnor Chester Rd #250
Show all (1)

Marinus Pharmaceuticals Financials and Metrics

Marinus Pharmaceuticals Revenue

USD

Net income (Q2, 2020)

(15.7m)

EBIT (Q2, 2020)

(15.9m)

Market capitalization (15-Jan-2021)

448.5m

Closing stock price (15-Jan-2021)

12.6

Cash (30-Jun-2020)

98.9m

EV

352.9m
Marinus Pharmaceuticals's current market capitalization is $448.5 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

General and administrative expense

3.2m5.5m6.2m6.7m8.8m11.5m

R&D expense

8.7m18.9m22.0m12.4m28.4m43.0m

Operating expense total

11.9m24.4m28.3m19.0m37.2m54.4m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

49.7m51.7m26.2m33.5m67.7m90.9m

Accounts Receivable

3.4m

Prepaid Expenses

978.0k1.2m2.5m

Inventories

428.0k1.6m199.0k
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(10.8m)(24.8m)(28.6m)(18.9m)(36.7m)(54.1m)

Depreciation and Amortization

5.0k11.0k23.0k126.0k127.0k278.0k

Inventories

39.0k278.9k

Accounts Payable

1.4m3.5m(629.0k)(2.1m)4.3m890.0k
USDQ2, 2014

Debt/Equity

-0.1 x

Debt/Assets

0.4 x

Financial Leverage

-0.1 x
Show all financial metrics

Marinus Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Marinus Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Marinus Pharmaceuticals Online and Social Media Presence

Embed Graph

Marinus Pharmaceuticals News and Updates

Thinking about buying stock in Marinus Pharmaceuticals, Fiat Chrysler, Lithium Americas, Xeris Pharmaceuticals, or Nokia?

NEW YORK, Sept. 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNS, FCAU, LAC, XERS, and NOK. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Marinus Pharmaceuticals to Present at SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum

RADNOR, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that management will present at SVB Leerink’s CybeRx Series: 2nd Annual CNS…

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., June 16, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the “Company” or “Marinus”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of an inducement award to a new empl…

Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

RADNOR, Pa., May 28, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the pricing of an underwritten public offering …

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results

Constructive End of Phase 2 Meeting with FDA for Status Epilepticus Completed in March; Pivotal Phase 3 Clinical Trial Expected to Begin Next Quarter

Marinus Pharmaceuticals Appoints Sasha Damouni Ellis as Vice President, Investor Relations and Corporate Communications

RADNOR, Pa., March 19, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat orphan seizure disorders, today announced the appointment of Sasha Damouni Ellis as Vice President, Investor Relat…
Show more

Marinus Pharmaceuticals Blogs

Marinus Pharmaceuticals Announces Public Offering of Common Stock

RADNOR, Pa. , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced that it intends to offer and sell 12,000,000 shares of its common stock in an underwritten public offering.  All of the shares in the offering are to be sold by

Marinus Pharmaceuticals to Present Ganaxolone Clinical Trial Data in CDKL5 Deficiency Disorder and PCDH19-Related Epilepsy at AES

RADNOR, Pa. , Nov. 19, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that two abstracts

Marinus Pharmaceuticals Names Dr. Rolando Gutíerrez-Esteinou as VP of Clinical Development and Pharmacovigilance

RADNOR, Pa. , Oct. 10, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced the appointment of Rolando Gutíerrez-Esteinou, M.D., as Vice

Marinus Completes Enrollment in its Magnolia Postpartum Depression Study

Marinus Completes Enrollment in its Magnolia Postpartum Depression Study Content Import Tue, 09/25/2018 - 07:33 Marinus Completes Enrollment in its Magnolia Postpartum Depression Study Sep 25, 2018 This release is a backfill from a News Wire Gen…

Scott Braunstein

Scott Braunstein Paul.alfano@na… Thu, 09/20/2018 - 10:52 Member of the Audit Scott Braunstein Director Dr. Braunstein brings over 20 years of knowledge and experience from diverse biotechnology and pharmaceutical industry vantage points. Dr. Braunstein is curren…

Marinus Pharmaceuticals to Present at Wedbush/PacGrow Healthcare Conference

Marinus Pharmaceuticals to Present at Wedbush/PacGrow Healthcare Conference Content Import Tue, 08/07/2018 - 07:33 Marinus Pharmaceuticals to Present at Wedbush/PacGrow Healthcare Conference Aug 7, 2018 This release is a backfill from a News Wire …
Show more

Marinus Pharmaceuticals Frequently Asked Questions

  • When was Marinus Pharmaceuticals founded?

    Marinus Pharmaceuticals was founded in 2003.

  • Who are Marinus Pharmaceuticals key executives?

    Marinus Pharmaceuticals's key executives are Scott Braunstein, Lisa M. Caperelli and Edward F. Smith.

  • How many employees does Marinus Pharmaceuticals have?

    Marinus Pharmaceuticals has 40 employees.

  • Who are Marinus Pharmaceuticals competitors?

    Competitors of Marinus Pharmaceuticals include Intarcia Therapeutics, CureVac and Synthetic Biologics.

  • Where is Marinus Pharmaceuticals headquarters?

    Marinus Pharmaceuticals headquarters is located at 170 N Radnor Chester Rd #250, Wayne.

  • Where are Marinus Pharmaceuticals offices?

    Marinus Pharmaceuticals has an office in Wayne.

  • How many offices does Marinus Pharmaceuticals have?

    Marinus Pharmaceuticals has 1 office.